Published in Blood Weekly, September 23rd, 2004
Under the agreement, the NCI will sponsor several clinical trials evaluating the activity of PXD101, either alone or in combination with other anticancer therapies, for the treatment of solid and hematologic cancers.
CuraGen licensed PXD101 from TopoTarget, A/S, and both companies are jointly developing PXD101 and additional HDAC inhibitors for use in oncology and other indications. As part of the DCTD...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.